keyword
MENU ▼
Read by QxMD icon Read
search

Onabotulinum

keyword
https://www.readbyqxmd.com/read/27879418/histopathologic-effects-of-onabotulinum-toxin-a-treatment-in-pediatric-submandibular-glands
#1
Ashley Mosseri, Isabel Cardona, Miriam Blumenkrantz, Sam J Daniel
Onabotulinum toxin A (OBTXA) is an effective treatment for drooling. Our objective was to determine if there are histologic changes in the submandibular glands (SMGs) after repetitive OBTXA injections. The study included blinded histologic analysis and comparison of SMGs with ≥4 OBTXA injections versus controls who never received OBTXA. The number of acinar cells were counted, and the morphology of the cells was evaluated within each histologic sample of the SMGs. Thirty-one glands were analyzed (14 control, 17 cases)...
November 22, 2016: Otolaryngology—Head and Neck Surgery
https://www.readbyqxmd.com/read/27709555/post-concussive-syndrome-a-focus-on-post-traumatic-headache-and-related-cognitive-psychiatric-and-sleep-issues
#2
Mia T Minen, Alexandra Boubour, Harjasleen Walia, William Barr
PURPOSE OF REVIEW: Post-traumatic headache (PTH) is a secondary headache disorder following traumatic brain injury. We sought to examine the recent literature on PTH and associated cognitive, psychiatric, and sleep conditions to understand the latest findings about the associated conditions and available screening tools, and to understand the available treatment options for PTH. RECENT FINDINGS: Up to one third of PTH patients may have depression and about one quarter may have insomnia...
November 2016: Current Neurology and Neuroscience Reports
https://www.readbyqxmd.com/read/27676714/long-term-real-life-efficacy-of-onabotulinum-toxin-a-for-the-treatment-of-neurogenic-detrusor-overactivity-in-a-population-using-intermittent-self-catheterization
#3
Charles Joussain, Mélanie Popoff, Véronique Phé, Alexia Even, Laetitia Falcou, Emmanuel Chartier-Kastler, Brigitte Schurch, Pierre Denys
OBJECTIVE: Intradetrusor injection of onabotulinum toxin A (IDIBA) is the third-line therapy for patients with neurogenic detrusor overactivity (NDO). There is few evidence of long-term efficacy but no study assessed reasons for failure or abandonment of IDIBA and CISC (clean intermittent self-catheterization) combined strategy. We aimed to assess its long-term outcome in NDO management, and analyze failure and discontinuation. MATERIALS/PATIENTS AND METHODS: We retrospectively reviewed medical records of patients admitted in our neurourology department between 2001 and 2013...
September 2016: Annals of Physical and Rehabilitation Medicine
https://www.readbyqxmd.com/read/27673152/poster-400-the-role-of-onabotulinum-toxin-a-in-a-comprehensive-treatment-approach-in-a-patient-with-complex-regional-pain-syndrome-a-case-report
#4
Matthew Drakeley, Peter J Hurh, Shanti M Pinto
No abstract text is available yet for this article.
September 2016: PM & R: the Journal of Injury, Function, and Rehabilitation
https://www.readbyqxmd.com/read/27636215/characterizing-the-bladder-s-response-to-onabotulinum-toxin-type-a-using-a-rat-model
#5
Alexis A Dieter, Jennifer M Wu, Nazema Y Siddiqui, Danielle J Degoski, Jillene M Brooks, Paul C Dolber, Matthew O Fraser
OBJECTIVES: The aim of this study was to characterize the response of the rat bladder neuromuscular system to intramural injection of onabotulinum toxin type A (BoNT/A) over 9 weeks using in vivo cystometry (CMG) and in vitro contractility (IVC). METHODS: Chronic bladder catheters were implanted in female Sprague-Dawley rats, and either (1) BoNT/A (10 units in 20 μL saline) or (2) saline (20 μL) was injected in 5 × 4 μL doses throughout the bladder wall. At 1, 3, 6, and 9 weeks after injection, conscious restrained CMG was performed...
November 2016: Female Pelvic Medicine & Reconstructive Surgery
https://www.readbyqxmd.com/read/27633917/gender-differences-in-onabotulinum-toxin-a-dosing-for-adductor-spasmodic-dysphonia
#6
Michael Z Lerner, Benjamin A Lerner, Amit A Patel, Andrew Blitzer
OBJECTIVES/HYPOTHESIS: The objective of this study was to determine the influence of gender on onabotulinum toxin A dosing for the treatment of adductor spasmodic dysphonia symptoms. STUDY DESIGN: Retrospective review. METHODS: A chart review of the senior author's database of botulinum toxin injections was performed. Patients diagnosed with adductor spasmodic dysphonia who received onabotulinum toxin A (BoNTA) injections to the thyroarytenoid muscle for at least 5 years were included for study...
September 16, 2016: Laryngoscope
https://www.readbyqxmd.com/read/27629059/new-medical-treatments-for-lower-urinary-tract-symptoms-due-to-benign-prostatic-hyperplasia-and-future-perspectives
#7
Simone Albisinni, Ibrahim Biaou, Quentin Marcelis, Fouad Aoun, Cosimo De Nunzio, Thierry Roumeguère
BACKGROUND: Lower Urinary Tract Symptoms (LUTS) in men are a common clinical problem in urology and have been historically strictly linked to benign prostatic hyperplasia (BPH), which may lead to bladder outlet obstruction (BOO). New molecules have been approved and have entered the urologists' armamentarium, targeting new signaling pathways and tackling specific aspects of LUTS. Objective of this review is to summarize the evidence regarding the new medical therapies currently available for male non-neurogenic LUTS, including superselective α1-antagonists, PDE-5 inhibitors, anticholinergic drugs and intraprostatic onabotulinum toxin injections...
September 15, 2016: BMC Urology
https://www.readbyqxmd.com/read/27564599/comparison-of-the-effectiveness-of-repeated-injections-of-onabotulinum-toxin-a-for-refractory-idiopathic-detrusor-overactivity-analysis-of-an-open-label-extension-of-a-randomized-trial-the-relax-study
#8
Rhiannon K Owen, Keith R Abrams, Christopher Mayne, Mark Slack, Douglas G Tincello
AIMS: To assess effects of repeat treatment with onabotulinumtoxin A (onaBoNT-A) in women with refractory idiopathic detrusor overactivity (DO). METHODS: Analysis of an open-label extension study of a large randomized placebo controlled trial of onaBoNT-A. Participants had been randomized to receive 200 IU onaBoNTA or placebo and were offered up to two further onaBoNTA injections over a 5-year period. For this analysis, the primary outcome was duration of treatment effect by patient-reported symptom return...
August 26, 2016: Neurourology and Urodynamics
https://www.readbyqxmd.com/read/27478469/botulinum-toxin-a-in-the-treatment-of-raynaud-s-phenomenon-a-systematic-review
#9
Paweł Żebryk, Mariusz J Puszczewicz
INTRODUCTION: The management of Raynaud's phenomenon in its most severe form is challenging, and current medical and surgical treatment methods frequently do not lead to optimal symptom control and prevention of ischemic complications. The aim of the study was to critically evaluate all existing evidence on the use of botulinum toxin A in the management of Raynaud's phenomenon. MATERIAL AND METHODS: We adopted the PRISMA methodology and searched Cochrane Library, MEDLINE, SCOPUS, EULAR and ACR congresses abstract archives for Raynaud* AND botulinum toxin OR onabotulinum...
August 1, 2016: Archives of Medical Science: AMS
https://www.readbyqxmd.com/read/27475516/injection-therapy-for-headache-and-facial-pain
#10
REVIEW
Jonathan K Kleen, Morris Levin
Peripheral nerve blocks are an increasingly viable treatment option for selected groups of headache patients, particularly those with intractable headache or facial pain. Greater occipital nerve block, the most widely used local anesthetic procedure in headache conditions, is particularly effective, safe, and easy to perform in the office. Adverse effects are few and infrequent. These procedures can result in rapid relief of pain and allodynia, and effects last for several weeks or months. Use of nerve block procedures and potentially onabotulinum toxin therapy should be expanded for patients with intractable headache disorders who may benefit, although more studies are needed for efficacy and clinical safety...
August 2016: Oral and Maxillofacial Surgery Clinics of North America
https://www.readbyqxmd.com/read/27395386/refractory-chronic-migraine-is-drug-withdrawal-necessary-before-starting-a-therapy-with-onabotulinum-toxin-type-a
#11
Calogera Butera, Bruno Colombo, Francesca Bianchi, Marco Cursi, Roberta Messina, Stefano Amadio, Roberta Guerriero, Giancarlo Comi, Ubaldo Del Carro
Onabotulinum toxin A (BT-A) is now one of the authorized prophylaxis treatments for chronic migraine (CM) thanks to previous clinical trials, which usually required a pharmacologic washout as a precondition for demonstrating its efficacy. Aim of our study was to assess the efficacy in daily clinical practice of BT-A injections in refractory CM patients, regardless of medication overuse without any standardized withdrawal protocol and without stopping the ongoing prophylaxis treatment as well. We treated 44 refractory CM patients (37 females and 7 males) trimonthly without any modification in symptomatic, or prophylactic drug therapy...
October 2016: Neurological Sciences
https://www.readbyqxmd.com/read/27272312/long-term-follow-up-of-intravesical-botulinum-toxin-a-injections-in-women-with-idiopathic-overactive-bladder-symptoms
#12
T A T Marcelissen, M S Rahnama'i, A Snijkers, B Schurch, P De Vries
INTRODUCTION: Intravesical botulinum toxin (BoNT-A) is a safe and effective treatment for overactive bladder syndrome. There are many reports on the clinical experience with BoNT-A, especially in patients with neurogenic detrusor overactivity. The US Food and Drug Administration has recently approved its use for idiopathic overactive bladder (iOAB). Various studies have reported positive results for iOAB in the short-term. Yet little is known about the results after repeated BoNT-A injections...
June 7, 2016: World Journal of Urology
https://www.readbyqxmd.com/read/27229889/real-life-clinical-practice-of-onabotulinum-toxin-a-intravesical-injections-for-overactive-bladder-wet-an-italian-consensus-statement
#13
Antonella Giannantoni, Antonio Carbone, Roberto Carone, Mauro Cervigni, Giulio Del Popolo, Enrico Finazzi Agrò, Gianfranco Giocoli Nacci, Giovanni Palleschi, Stefano Salvatore, Michele Spinelli, Andrea Tubaro
PURPOSE: We developed a consensus on best practice in the real-life management of patients with overactive bladder (OAB) with onabotulinumtoxin A (Onabot/A). METHODS: In March 2015, an interdisciplinary conference was convened. Eleven panelists were invited to review the literature, to present their personal experience and to respond to a number of questions from: "when do we propose Onabot/A treatment" to "when do you decide to re-inject a patient?" A summary of findings of the meeting was provided to all panelists for review and approval...
May 26, 2016: World Journal of Urology
https://www.readbyqxmd.com/read/27181448/intraoral-administration-of-botulinum-toxin-for-trigeminal-neuropathic-pain
#14
Alberto Herrero Babiloni, Flavia P Kapos, Donald R Nixdorf
This article presents 2 cases of different neuropathic trigeminal pain conditions treated with intraoral botulinum toxin injections. There is a growing body of evidence to support the use of this substance when administered subcutaneously in the treatment of neuropathic pain, such as in extraoral injections for trigeminal neuralgia. However, reports of intraoral submucosal administration are still lacking. In the 2 cases presented here, neuropathic pain was refractory to treatment with an important intraoral peripheral component, so onabotulinum toxin A was introduced as an adjuvant therapy...
June 2016: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
https://www.readbyqxmd.com/read/27177451/safety-profile-of-incobotulinum-toxin-a-xeomin-%C3%A2-in-gastrocnemious-muscles-injections-in-children-with-cerebral-palsy-randomized-double-blind-clinical-trial
#15
Elena Carraro, Enrico Trevisi, Andrea Martinuzzi
BACKGROUND: The only two preparations of botulinum toxin A for which there are published evidences of efficacy in children with cerebral palsy are onabotulinum toxin A (Botox(®)) and abobotulinum toxin A (Dyport(®)); these toxins should be considered generally safe and appropriate in the treatment for localized upper and lower limb spasticity. AIMS: To establish the safety profile of incobotulinum toxin A (Xeomin(®)) in children with cerebral palsy and muscle spasticity...
December 0: European Journal of Paediatric Neurology: EJPN
https://www.readbyqxmd.com/read/27144785/effect-of-onabotulinum-toxin-a-on-substance-p-and-receptor-neurokinin-1-in-the-rat-ventral-prostate
#16
Omer Onur Cakir, Carol A Podlasek, Douglas Wood, Kevin E McKenna, Kevin T McVary
INTRODUCTION: The objective of this work is to examine if sensory innervation impacts lower urinary tract symptoms (LUTS). Onabotulinum toxin A (BoNTA) has been used for the treatment of overactive and neurogenic bladder and as a treatment for LUTS secondary to benign prostatic hyperplasia (BPH). The mechanism of how BoNTA impacts LUTS/BPH is unclear. In rats, BoNTA injection causes prostate denervation, apoptosis and atrophy. In clinical trials reduced prostate size and LUTS are observed inconsistently, suggesting a neurologic component...
June 2015: Andrology: Open Access
https://www.readbyqxmd.com/read/27136635/innovative-use-of-chemodenervation-in-the-treatment-of-postoperative-genital-hyperhidrosis-like-symptoms
#17
Kelly R Stiegel, Eman Bahrani, Ramsey F Markus
Postoperative complications present in many forms and can cause great morbidity and even mortality in patients who experience them. Frey syndrome is an example of a postoperative complication in which aberrant nerve regeneration following parotidectomy leads to hyperhidrosis induced by gustatory stimuli. We present a unique but similar case of aberrant nerve regeneration and resulting hypersecretion that emerged 6-7 months following perineoplasty and labial reduction for lichen sclerosus in a 53-year-old woman...
2016: Dermatology Online Journal
https://www.readbyqxmd.com/read/27130542/interventional-treatment-for-post-traumatic-headache
#18
REVIEW
Francis X Conidi
Post-traumatic headache (migraine) is the most common symptom of concussion and traumatic brain injury. An expert opinion-based review along with a literature review (PubMed) was conducted looking at known interventional procedures for post-traumatic headache using the keywords post-traumatic headache, post-traumatic migraine headache, concussion, mild traumatic brain injury, and traumatic brain injury and the following categories: mechanism, pathophysiology, treatment, physical therapy, neurostimulation, Botox@/Onabotulinum toxin, and surgical intervention...
June 2016: Current Pain and Headache Reports
https://www.readbyqxmd.com/read/27122065/botulinum-toxin-for-foot-dystonia-in-patients-with-parkinson-s-disease-having-deep-brain-stimulation-a-case-series-and-a-pilot-study
#19
Anupam Datta Gupta, Renuka Visvanathan
BACKGROUND: Six patients with Parkinson's disease with deep brain stimulation who were experiencing disabling foot dystonia were referred to the spasticity clinic for a trial of botulinum toxin. The foot and ankle muscles were injected with onabotulinum toxin (Botox) to determine the effects on foot dystonia, pain and lower limb functional outcomes. DESIGN: Case series. SUBJECTS/PATIENTS: Six patients with Parkinson's disease with deep brain stimulation experiencing disabling foot dystonia...
June 13, 2016: Journal of Rehabilitation Medicine
https://www.readbyqxmd.com/read/27111192/intravesical-instillation-of-onabotulinum-toxin-a-embedded-in-inert-hydrogel-in-the-treatment-of-idiopathic-overactive-bladder-a-double-blind-randomized-pilot-study
#20
Jan Krhut, Marie Navratilova, Radek Sykora, Michaela Jurakova, Marcel Gärtner, David Mika, Lubomir Pavliska, Peter Zvara
OBJECTIVE: It was hypothesized that increasing the time for which onabotulinum toxin A (OnabotA) is exposed to the urothelium following intravesical instillation will augment its effect. TC-3 is an inert heat-sensitive hydrogel, which creates an intravesical bulk providing a slow release of the embedded drug after instillation. The aim of this study was to evaluate the effect of OnabotA, embedded in inert TC-3 hydrogel, in patients with idiopathic overactive bladder (OAB). METHODS: In total, 39 female patients (age 30-65, average 53...
June 2016: Scandinavian Journal of Urology
keyword
keyword
22193
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"